Understanding innovation of health technology assessment methods: the IHTAM framework

Abstract

Adequate methods are urgently needed to guarantee the good practice of health technology assessment (HTA) for technologies with novel properties. The aim of the study was to construct a conceptual framework to help understand the innovation of HTA methods (IHTAM). The construction of the IHTAM framework was based on two scoping reviews, one on the current practice of innovating methods, that is existing HTA frameworks, and one on theoretical foundations for innovating methods outside the HTA discipline. Both aimed to identify and synthesize concepts of innovation (i.e., innovation processes and roles of stakeholders in innovation). Using these concepts, the framework was developed in iterative brainstorming sessions and subsequent discussions with representatives from various stakeholder groups. The framework was constructed based on twenty documents on innovating HTA frameworks and fourteen guidelines from three scientific disciplines. It includes a generic innovation process consisting of three phases (“Identification,” “Development,” and “Implementation”) and nine subphases. In the framework, three roles that HTA stakeholders can play in innovation (“Developers,” “Practitioners,” and “Beneficiaries”) are defined, and a process on how the stakeholders innovate HTA methods is included. The IHTAM framework visualizes systematically which elements and stakeholders are important to the development and implementation of novel HTA methods. The framework could be used by all stakeholders involved in HTA innovation to learn how to engage dynamically and collaborate effectively throughout the innovation process. HTA stakeholders in practice have welcomed the framework, though additional testing of its applicability and acceptance is essential.

How therapeutic advances have transformed the medical landscape: a primer for clinicians

“…25 Trials with more complex designs inevitably generate evidence of safety, efficacy and value (or whatever outcome is being measured) that is more difficult to interpret. 26 This means that regulators and payers need to be cognisant of the strengths and limitations of the data with which they are presented and the context in which these trials have been conducted, particularly with regard to the availability of existing therapeutic options. For example, assessment of novel treatments for a rare cancer for which there is currently no effective treatment is quite a different scenario from assessment of a third disease-modifying agent for an immune-mediated neurological condition, such as multiple sclerosis, where other similar agents are already on the market and broadly accessible.…”

“…The increasing complexity of clinical trials poses challenges for those conducting health technology assessments of medicines to determine whether they should be registered or subsidised 25 . Trials with more complex designs inevitably generate evidence of safety, efficacy and value (or whatever outcome is being measured) that is more difficult to interpret 26 . This means that regulators and payers need to be cognisant of the strengths and limitations of the data with which they are presented and the context in which these trials have been conducted, particularly with regard to the availability of existing therapeutic options.…”

Circulating Biomarkers for Cancer Detection: Could Salivary microRNAs Be an Opportunity for Ovarian Cancer Diagnostics?

“…For example, there are studies dealing with tumor DNA detection, also for methylation profiling, in liquid cytology samples from vagina and endocervix, including routinely collected cervical screening specimens, vaginal self-swab and tampons, and uterine lavage samples. Moreover, improvements in imaging methods are pursued to include refinements of TVS, Doppler flow, microbubble contrast-enhanced TVS, and photo-acoustic imaging, all of which allow high-resolution detection of angiogenesis with the potential to detect neovascularization in early cancers [ 26 , 27 , 28 ]. In addition, multi-omics technologies (genomics, transcriptomics, proteomics, and metabolomics) hold the possibility of discovering new informative BMs [ 29 , 30 ] in signature panels.…”